GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550

GT Biopharma, Inc.

Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
University of Minnesota will sponsor as investigator-initiated Phase 1a/1b trial.
Budget of up to $3.8 million over three years, funded by GT Biopharma.
Agreement effective April 3, 2026; 30-day termination clause for either party.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.